For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
the ONA take:
According to a new study published in the journal Science Signaling, a team of researchers from around the world has demonstrated that more than 80% of colorectal cancers could be treated with Janus kinase (JAK) inhibitors. For the study, researchers tested JAK inhibitors in preclinical models of colorectal cancer and human colorectal cancer cells that have elevated levels of Wnt signaling.
A genetic mutation triggers increases levels Wnt pathway signaling, which in turn triggers more than 80% of colorectal cancers. According to the researchers, targeting the Wnt signaling pathway is difficult because normal cells in the intestine require low levels of Wnt signaling to maintain the healthiness of the gut.
The researchers sought to determine whether another signaling pathway, which involves JAK proteins, could be targeted to decrease tumor growth without harming the normal cells of the intestine. They found that inhibiting JAKs could halt cancer growth and no adverse effects were observed in the preclinical models; however, JAK inhibitors were only effective when the colorectal tumors were triggered by defective Wnt signaling, which is about 80-90% of colorectal cancers.
There are currently no JAK inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer.
More than 80% of colorectal cancers could be treated with Janus kinase inhibitors
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|